Update on indications for treatment of Helicobacter pylori (including Maastricht 2)

Current Opinion in Gastroenterology

Volumn 17, Issue SUPPL. 1, 2001, Pages

  Goh, Khean Lee ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0003095983     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Malfertheiner P, et al. Current Concepts in the Management of Helicobacter pylori Infection. Proceedings of the Maastricht 2 Consensus Meeting. Maastricht, The Netherlands; September 2000. http://helicobacter.org/ ehpsg_guidelines_patients_2000.htm; April 2001.
2. Coelho LGV, LeonBarua R, Quigley EMM. Latin-American Consensus conference on Helicobacter pylori infection. Am J Gastroenterol 2000; 95:2688-26891.
3. Lai KC, Hui WM, Wong WM, et al. Treatment of Helicobacter pylori in patients with duodenal ulcer hemorrhage- along term randomized, controlled study. Am J Gastroenterol 2000; 95:2225-2232.
4. Ng EK, Lam YH, Sung JJ, et al. Eradication of Helicobacter pylori prevents recurrence of ulcer after simple closure of duodenal ulcer perforation: randomized controlled trial. Ann Surg 2000; 231:153-158.
5. Taskin V, Gurer I, Ozyilkan E, et al. Effect of Helicobacter pylori eradication on peptic ulcer disease complicated with outlet obstruction. Helicobacter 2000; 5:38-40.
6. Papa A, Cammarota G, Tursi A, et al. Helicobacter pylori eradication and remission of low-grade mucosa-associate lymphoid tissue lymphoma: a long-term follow-up study. J Clin Gastroenterol 2000; 31:169-171.
7. Fischbach W, Dragosics B, Kolve Goebeler ME, et al. Primary gastric B-cell lymphoma: results of a prospective multicenter study. Gastroenterology 2000; 119:1191-1202. Emphasizes the importance of accurate diagnosis and staging of primary gastric B-cell lymphoma in the choice of treatment. H. pylori eradication is the treatment of choice in low-grade lymphoma, Stage E1.
8. Morgner A, Lehn N, Andersen LP, et al. Helicobacter heilmanii-associated primary gastric low-grade lymphoma: complete remission after curing the infection. Gastroenterology 2000; 118:821-828.
9. Konturek PC, Konturek SJ, Starzyska T, et al. Helicobacter pylori-gastrin link in MALT lymphoma. Aliment Pharmacol Ther 2000; 14:1311-1318.
10. Kuipers EJ, Leundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux oesophagitis terated with omeprazole or fundoplication. N Engl J Med 1996; 334:1018-1022.
11. Schenk BE, Kuipers EJ, Nelis GF, et al. Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut 2000; 46:615-621.
12. Uemura N, Okamato S, Yamato S, et al. Helicobacter pylori infection and the development of gastric cancer: second report - long term endoscopic follow-up study [abstract]. Gastroenterology 2000; 118:A726.
13. Stone MA, Taub N, Barnett DB, Mayberry JF. Increased risk of infection with Helicobacter pylori in spouses of infected subjects: observations in general practipopulation sample from UK. Hepatogastroenterology 2000; 47:433-436.
14. Zhou H, Chan KL, Chu KM, Tam PKH. Intrafamilial spread of Helicobacter pylori: a prospective study using urea breath test. J Pediatr Surg 2000; 35:1672-1675.
15. Koletzko S, Demmelmair H, Kindetrmann A. Helicobacter amongst siblings. Lancet 2000; 355:1998-1999.
16. Bakir T, Can G, Ekrul S, Siviloglu C. Stomach cancer history in the siblings of patients with gastric carcinoma. Eur J Cancer Prev 2000; 9:401-408.
17. El-Omar EM, Oien K, Murray LS, et al. Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of Helicobacter pylori, Gastroenterology 2000; 118:22-30. Relatives of patients with gastric cancer have an increased prevalence or precancerous abnormalities, but this is confined to those with H. pylori infection.
18. El-Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000;404: 398-402. An outstanding paper that shows that increased production of interleukin 1-beta is associated with increased risk of both hypochlorydria induced by H. pylori and gastric cancer.
19. Yamagata H, Kiyohara Y, Aoyagi K, et al. Impact of Helicobacter pylori infection on gastric cancer incidence in a general Japanese population. Arch Intern Med 2000; 160:1962-1968. A long-term longitudinal cohort follow-up study from Japan, which showed a significant association between infection with H. pylori and subsequent gastric cancer in males.
20. Moayyedi P, Soo S, Deeks J, et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Br Med J 2000; 321:659-664. Systematic review and cost-effective analysis on eradication of H. pylori for non-lever dyspepsia.
21. McColl K. Should non-invasive Helicobacter pylori testing replace endoscopy in investigation of dyspepsia? Helicobacter 2000; 5(suppl 1): S11-S15.
22. Delaney BC, Wilson S, Roaffe A, et al. Randomised controlled trial of Helicobacter pylori testing and endoscopy for dyspepsia in primary care. Br Med J 2001; 322:898-901. A test and endoscope approach was not shown to lower costs or improve patients' symptoms or quality of life.
23. Labenz J, Blum AL, Bayerdoffer E, et al. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux oesophagitis. Gastroenterology 1997; 112:1442-1447.
24. Hamada H, Haruma K, Mihara M, et al. High incidence of reflux oesophagitis after eradication therapy of Helicobacter pylori: impacts of hiatal hernia and corpus gastritis. Aliment Pharmacol Ther 2000; 14:729-735.
25. Murai T, Miwa H, Ohkura R, et al. The incidence of reflux oesophagitis after cure of Helicobacter pylori in a Japanese population. Aliment Pharmacol Ther 2000; 14:161-165.
26. Rinaldi V, Morini S, Zullo A, et al. Reflux oesophagitis after Helicobacter pylori treatment [letter]. Dig Liver Dis 2000; 32:749.
27. Wu JCY, Sung JJY, Chan FKL, et al. Helicobacter pylori infection is associated with milder gastroesophageal reflux disease. Aliment Pharmacol Ther 2000; 14:427-432.
28. Voutilainen M, Sipponen P, Mecklin JP, et al. Gastroesophageal reflux disease: prevalence, clinical, endoscopic and histopathological findings in 1,128 consecutive patients referred for endoscopy due to dyspeptic and reflux symptoms. Digestion 2000; 61:6-13.
29. Vieth M, Masoud B, Meining A, Stolte M. Helicobacter pylori infection: protection against Barrett's mucosa and neoplasia? Digestion 2000; 62:225-231.
30. Van Herwarrden MA, Samson M, Smout AJPM. Helicobacter pylori eradication increases nocturnal acid breakthrough [letter]. Aliment Pharmacol Ther 2000; 14:961-962.
31. Katsube T, Adachi K, Kawamura A, et al. Helicobacter pylori infection influences nocturnal acid breakthrough. Aliment Pharmacol Ther 2000; 14:1049-1056.
32. Hawkey CJ. Risk of ulcer bleeding in patients infected with Helicobacter pylori taking non-steroidal anti-inflammatory drugs. Gut 2000; 46: 310-311. A prospective case-control study which showed that H. pylori-infected NSAID users had double the risk of bleeding compared with uninfected NSAID users.
33. Chan FKL, Sung JJY, Chung SCS, et al. Randomized trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory therapy to prevent peptic ulcers. Lancet 1997; 350:975-979.
34. Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344:967-973.
35. Sung JJY, Russell RI, Yeomans N, et al. NSAID toxicity in the upper gastrointestinal tract. J Gastroenterol Hepatol 2000; 15(suppl):C61-C72. A Working Party report on NSAID toxicity in general from the Asian-Pacific region.